EXECUTIVE COMPENSATION AND OTHER INFORMATION
Our Executive Officers
The following
table sets forth information regarding our executive officers as of March 30, 2018:
|
|
|
|
|
Name
|
|
Age
|
|
Position(s)
|
Thomas J. Schall, Ph.D.
|
|
58
|
|
President, Chief Executive Officer and Chairman
|
William C. Fairey Jr.
|
|
53
|
|
Executive Vice President, Chief Operating Officer
|
Susan M. Kanaya
|
|
55
|
|
Executive Vice President, Chief Financial and Administrative Officer and
Secretary
|
Markus J. Cappel, Ph.D.
|
|
57
|
|
Chief Business Officer and Treasurer
|
Jan L. Hillson, M.D., Ph.D.
|
|
65
|
|
Senior Vice President, Drug Development
|
Rajinder Singh, Ph.D.
|
|
51
|
|
Senior Vice President, Research
|
The biography of Thomas J. Schall, Ph.D. can be found under Proposal 1Election of Directors.
William C. Fairey Jr.
has served as our Executive Vice President, Chief Operating Officer since January 2018. Prior to joining us,
Mr. Fairey served in numerous positions with Actelion Pharmaceuticals Ltd., most recently as President of Actelion Pharmaceuticals US, from 2013 to 2017, where he led Actelions sales, marketing, medical, access and regulatory activities.
Prior to this, he served as Head of Actelions Asia Pacific Region from 2008 to 2012 and President of Actelion Pharmaceuticals, Canada, from 2003 to 2008. Mr. Fairey started his pharmaceutical career with Parke-Davis US, where he held
various positions on the commercial side of the business. Mr. Fairey received his B.S. in Biology from the University of Oregon and his M.B.A. from Saint Marys College, California.
Susan M. Kanaya
has served as our Executive Vice President, Chief Financial and Administrative Officer since October 2016 and as
Secretary since February 2006. From January 2006 to October 2016, Ms. Kanaya served as our Senior Vice President, Finance, and Chief Financial Officer. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief
Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President,
Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.
Markus J. Cappel, Ph.D.
has served as our Chief Business Officer since February 2007, and Treasurer since August 2004. From March 2003
to February 2007, he served as our Senior Vice President of Corporate and Business Development. From October 2001 to March 2003, Dr. Cappel served as our Vice President of Business Development. Prior to joining us, Dr. Cappel served as
Vice President of Business Development at Alkermes, Inc., a biotechnology company, from 1998 to 2001. Prior to this, he served as Director of Business Development with Millennium Pharmaceuticals as well as in various business development roles at
Cygnus, Inc., a biotechnology company. Dr. Cappel received his B.S. in pharmacy and his Ph.D. in pharmaceutics from J.W. Goethe University, Frankfurt, Germany, and his M.B.A. from Harvard Business School. Dr. Cappel also completed
postdoctoral studies in pharmaceutics at the University of Michigan.
Jan L. Hillson, M.D., Ph.D.
has served as our Senior Vice
President, Drug Development since November 2016. From 2013 to 2016, Dr. Hillson served as Vice President of Clinical and Translational Research at Momenta Pharmaceuticals. From 2007 to 2013, she served as Senior Director at ZymoGenetics/Bristol
Myers Squibb, leading Clinical Research and Pharmacology for projects in immunology and immuno-virology. Prior to 2007, Dr. Hillson served in several positions, including Medical Director at Xcyte Therapies, Clinical Faculty at Harvard Medical
School (Cambridge Health Alliance), Assistant Professor at University of Washington and Division Head at Virginia Mason Medical Center providing consultative and direct patient care, with a
24